Extending regulatory accountability across the pharmaceutical supply chain is essential for patient safety. Discuss with reference to Schedule H, H1 and X drugs.

Schedule H, H1 and X drugs may be sold only on a Registered Medical Practitioner's prescription [2]. Since 2015, however, only manufacturers needed prior Central sanction to advertise them [3]. The draft G.S.R. 861(E) (September 2026) extends this curb to retailers, wholesalers and distributors [1]. It recognises that patient safety depends on every link in the chain, not only on the producer.

Why supply-chain accountability is essential

• Curbing self-medication: when pharmacies promote antibiotics and psychotropics, people take them without medical supervision [1].
• AMR and TB control: Schedule H1 covers 3rd/4th-generation antibiotics, anti-TB drugs and habit-forming drugs [2]. Misuse breeds resistance and weakens TB treatment.
• Closing the loophole: sellers and distributors were not explicitly covered. The draft adds sub-rule (22) to Rule 65, which lists the conditions of a sale licence [1][4].
• Traceability: each H1 sale is entered in a separate register with the prescriber, patient, drug and quantity, and kept for 3 years [2]. Records like this make the retailer answerable.
• Expert-led, participatory rule-making: the 93rd DTAB meeting recommended the change [1]. DTAB is the statutory adviser under Section 5 of the 1940 Act [5]. The public has 30 days to file objections [1].

Limitations

• The counter sale is the core problem: selling antibiotics without a prescription involves no advertisement at all.
• Centre–State gap: the Centre grants sanction, but State Licensing Authorities enforce [3]. Without a public list of sanctions, inspectors cannot easily tell legal ads from illegal ones.
• Digital blind spot: apps and influencers without a sale licence fall outside the rule. The DMR Act, 1954 covers only listed diseases and "magic" claims [6].
• Uneven paper trail: the much longer Schedule H list has no sale register.
• Price notices caught in the net: plain discount notices may need sanction, which could hurt chronic patients who buy medicines every month.

Way forward

• Define "advertisement" broadly, borrowing the DMR Act's wording and adding apps and social media [6].
• Exempt general price lists that name no drug, and publish every sanction granted.
• Audit H1 registers alongside advertising compliance.

Extending accountability from the manufacturer to the chemist's counter is a needed step against self-medication and AMR. Combined with digital coverage, Centre–State coordination and prescription audits, it can turn the right to health under Article 21 and SDG 3 into safe medicine use for every patient.